PTC Therapeutics posts results of Phase 3 ataluren safety study in Duchenne muscular dystrophy
Results for the open-label safety study of ataluren (PTC124) in 265 participants with nonsense mutation dystrophinopathy were first posted on ClinicalTrials.gov on October 8, 2026. The study, which began on November 22, 2010 and reached primary completion on February 10, 2026, was terminated before completion.
Primary source
ClinicalTrials.gov results record, October 8, 2026
Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)
Read the source: Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation